FHIR
© HL7.org |
FHIRsmith
4.0.1 |
Server Home
|
XIG Home
|
XIG Stats
|
FHIR IG analytics
Version:
All
|
R2
|
R2B
|
R3
|
R4
|
R4B
|
R5
|
R6
Authority:
All
|
hl7
|
ihe
|
national
Realm:
All
|
au
|
be
|
br
|
ca
|
ch
|
cl
|
cr
|
cz
|
de
|
dk
|
ee
|
eu
|
fi
|
fr
|
il
|
in
|
it
|
jp
|
kr
|
nl
|
no
|
nz
|
pl
|
pt
|
se
|
stt
|
tw
|
uk
|
us
|
uv
View:
All
|
Resource Profiles
|
Datatype Profiles
|
Extensions
|
Logical Models
|
CodeSystems
|
ValueSets
|
ConceptMaps
ValueSets
84,592 resources (
JSON
|
CSV
)
Source:
SNOMED-CT
LOINC
UCUM
NDC
CVX
ISO Standard
IETF
IHE
ICPC Variant
NCPDP
NUCC
ICD-X
OID-Based
DICOM
CPT
RxNorm
terminology.hl7.org
hl7.org/fhir
Internal
Example
VSAC
ATC
NCI-Thesaurus
X12
CMS (USA)
CDC (USA)
Sequence Codes
Text:
Package:
Only Show Used
By Version
R2
: 25
R2B
: 0
R3
: 7,398
R4
: 53,095
R4B
: 14,934
R5
: 8,882
R6
: 143
By Authority
none: 44,145
hl7
: 38,380
ihe
: 143
national
: 1,376
who
: 548
By Realm
none: 41,876
au
: 99
be
: 131
br
: 122
ca
: 515
ch
: 416
cl
: 162
cr
: 14
cz
: 103
de
: 575
dk
: 498
ee
: 35
eu
: 386
fi
: 4
fr
: 909
il
: 161
in
: 48
it
: 92
jp
: 71
kr
: 20
nl
: 916
no
: 16
nz
: 9
pl
: 70
pt
: 3
se
: 16
tw
: 220
us
: 14,248
uv
: 22,853
other: 4
Start
Prev
Rows 41400 - 41600
Next
Package
Version
Identity
Name/Title
Status
FMM
WG
Date
Realm
Auth
Source(s)
Usage #
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.168.json
Moxetumomab Injectable
active
2021-05
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.169.json
Necitumumab Injectable
active
2021-05
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.170.json
Nelarabine Injectable
active
2021-05
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.171.json
Temsirolimus Injectable
active
2021-05
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.172.json
Tisagenlecleucel Injectable
active
2021-05
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.173.json
Topotecan Injectable
active
2021-05
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.178.json
Atezolizumab Injectable
active
2024-11
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.179.json
Avelumab Injectable
active
2024-11
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.180.json
Bleomycin Injectable
active
2024-11
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.181.json
Cemiplimab Injectable
active
2024-11
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.182.json
Cladribine Injectable
active
2021-05
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.183.json
Daratumumab Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.184.json
Durvalumab Injectable
active
2024-11
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.185.json
Emapalumab Injectable
active
2024-11
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.186.json
Fludarabine Injectable
active
2021-05
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.187.json
Ipilimumab Injectable
active
2024-11
us
hl7
rx
2
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.188.json
Nivolumab Injectable
active
2024-11
us
hl7
rx
2
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.189.json
Pembrolizumab Injectable
active
2024-12
us
hl7
rx
2
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.190.json
Polatuzumab Vedotin Injectable
active
2021-07
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.191.json
Pralatrexate Injectable
active
2021-07
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.192.json
Vincristine Injectable
active
2021-07
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.193.json
Methotrexate Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.194.json
Trastuzumab Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.195.json
Mitomycin Injectable
active
2021-05
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.196.json
Brentuximab Vedotin Injectable
active
2021-05
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.197.json
Doxorubicin Pegylated Liposomal Injectable
active
2024-11
us
hl7
rx
2
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.198.json
Blinatumomab Injectable
active
2024-11
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.199.json
Trastuzumab Emtansine Injectable
active
2021-05
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.200.json
Gemtuzumab Ozogamicin Injectable
active
2021-05
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.201.json
Tagraxofusp Injectable
active
2024-12
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.202.json
Axicabtagene Ciloleucel Injectable
active
2024-11
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.203.json
BRCA1
active
2023-06
us
hl7
loinc
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.204.json
BRCA2
active
2023-06
us
hl7
loinc
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.205.json
BRCA1 Testing
active
2023-06
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.207.json
Epithelial Ovarian Cancer
active
2024-08
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.208.json
Primary Peritoneal Cancer
active
2022-06
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.209.json
Fallopian Tube Cancer
active
2022-06
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.210.json
Multigene Panel
active
2023-07
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.211.json
BRCA1 and BRCA2
active
2023-06
us
hl7
loinc
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.212.json
BRCA1 and BRCA2 Testing
active
2023-06
us
hl7
cpt
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.213.json
BRAF V600
active
2022-01
us
hl7
loinc
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.214.json
BRAF V600 Testing
active
2023-04
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.215.json
Colorectal Cancer
active
2024-08
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.216.json
BRAF V600 Mutation Status
active
2022-01
us
hl7
loinc
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.217.json
Cancer Stage I
active
2024-08
us
hl7
sct
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.218.json
Head and Neck Cancer
active
2022-02
us
hl7
icd
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.219.json
Malignant Melanoma of Skin
active
2022-06
us
hl7
icd
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.220.json
Brain Cancer
active
2022-07
us
hl7
icd
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.221.json
Waldenstrom Macroglobulinemia
active
2024-08
us
hl7
icd
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.222.json
High Emetic Risk Intravenous Antineoplastic Agent
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.223.json
Moderate Emetic Risk Intravenous Antineoplastic Agent
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.224.json
Docetaxel Injectable
active
2024-12
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.225.json
Cyclophosphamide Injectable
active
2022-09
us
hl7
rx
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.226.json
LAG 3 Inhibitor
active
2024-11
us
hl7
rx
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.233.json
Chemotherapy Administration
active
2024-01
us
hl7
cms
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.240.json
Pathological N Stage N3c
active
2024-09
us
hl7
sct
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.241.json
Audio Visual Telehealth Encounter
active
2025-01
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.242.json
Moderate or High Emetic Risk Oral Antineoplastic Agent
active
2025-04
us
hl7
rx
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.243.json
Minimal to Low Emetic Risk Oral Antineoplastic Agent
active
2025-04
us
hl7
rx
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.244.json
Copanlisib Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.245.json
Isatuximab Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.246.json
Loncastuximab tesirine Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.247.json
Margetuximab Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.248.json
Mirvetuximab soravtansine Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.249.json
Tafasitamab Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.250.json
Teclistamab Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.251.json
Tisotumab Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.252.json
Asparaginase Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.254.json
Belantamab Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.255.json
Dostarlimab Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.256.json
Mosunetuzumab Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.257.json
Tremelimumab Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.258.json
Indication for Dexamethasone
active
2025-04
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.260.json
Indication for Olanzapine
active
2025-04
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.261.json
Indication for Dexamethasone
active
2025-04
us
hl7
icd
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.263.json
Indication for Olanzapine
active
2025-04
us
hl7
icd
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.264.json
Prednisone
active
2025-04
us
hl7
rx
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.265.json
As Needed PRN
active
2025-04
us
hl7
sct
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.3.266.json
Amivantamab Injectable
active
2025-04
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.200.json
Doxorubicin
active
2020-09
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.201.json
Epirubicin
active
2020-09
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.202.json
Capecitabine
active
2023-06
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.203.json
Cyclophosphamide
active
2020-09
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.204.json
Injectable Fluorouracil
active
2020-09
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.205.json
Methotrexate
active
2020-09
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.206.json
Trastuzumab and Biosimilars
active
2020-09
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.207.json
HER2 Presence in Tissue
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.208.json
Carboplatin
active
2020-09
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.209.json
Depression Screening for Adult
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.210.json
Long Acting Opioids
active
2020-10
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.211.json
High Fiber Supplement or Diet Education
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.212.json
Dexamethasone
active
2021-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.213.json
Olanzapine
active
2021-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.214.json
Pancreatic Cancer
active
2020-10
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.215.json
Audio Visual Telehealth Encounter
active
2025-02
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.216.json
Telephone Encounter
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.217.json
Telehealth Emergency Department or Initial Inpatient
active
2024-07
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.218.json
Dyspnea Assessment
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.219.json
Nausea or Vomiting Assessment
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.220.json
Karnofsky Performance Status
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.221.json
Referral to Hospice Care
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.222.json
Referral to Palliative Care
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.223.json
Palliative Care
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.224.json
Enrollment in Hospice Care
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.225.json
Advance Directive Including Durable Power of Attorney or Instructional
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.229.json
Minimal Emetic Risk Intravenous Antineoplastic Agent
active
2025-04
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.232.json
Epithelial Ovarian Cancer
active
2023-06
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.233.json
Primary Peritoneal Cancer
active
2022-06
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.235.json
BRCA2 Testing
active
2023-06
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.236.json
Multigene Panel
active
2023-07
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.237.json
BRCA1 Testing
active
2023-06
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.238.json
First Line Drug Therapy for Metastatic Colorectal Cancer
active
2022-01
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.239.json
BRAF V600 Testing
active
2022-01
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.240.json
Cancer Stage 4
active
2022-01
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.241.json
Cancer Stage M1
active
2024-12
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.242.json
High Emetic Risk Intravenous Antineoplastic Agent
active
2022-09
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.243.json
Moderate Emetic Risk Intravenous Antineoplastic Agent
active
2024-10
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.245.json
Antiemetic Agent
active
2025-04
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.247.json
Indication for Dexamethasone
active
2025-04
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.1444.5.249.json
Indication for Olanzapine
active
2025-04
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.2074.1.1.3.json
Race Category Excluding Nulls
active
2024-06
us
hl7
oid
2
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.1002.77.json
Codeine
active
2024-02
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.1004.13.json
Dihydrocodeine
active
2024-02
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.1004.14.json
Nalbuphine
active
2020-03
us
hl7
rx
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4009.json
Malignant Intracranial Neoplasm
active
2024-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4010.json
Malignant Intracranial Neoplasm
active
2023-02
us
hl7
icd
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4015.json
STEMI
active
2022-02
us
hl7
icd
2
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4016.json
STEMI
active
2019-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4017.json
STEMI
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4019.json
Fibrinolytic Therapy
active
2023-02
us
hl7
rx
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4023.json
Cerebral Vascular Lesion
active
2025-02
us
hl7
icd
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4024.json
Cerebral Vascular Lesion
active
2025-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4025.json
Cerebral Vascular Lesion
active
2019-02
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4026.json
Closed Head and Facial Trauma
active
2019-02
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4028.json
Aortic Dissection or Ruptured Aortic Aneurysm
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4029.json
Acute Peptic Ulcer
active
2023-02
us
hl7
icd
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4030.json
Acute Peptic Ulcer
active
2023-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4031.json
Acute Peptic Ulcer
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4032.json
Dementia and Related Intracranial Pathologies
active
2025-02
us
hl7
icd
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4033.json
Dementia and Related Intracranial Pathologies
active
2025-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4034.json
Active Bleeding or Bleeding Diathesis, Excluding Menses
active
2025-02
us
hl7
icd
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4035.json
Active Bleeding or Bleeding Diathesis, Excluding Menses
active
2022-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4036.json
Active Bleeding or Bleeding Diathesis, Excluding Menses
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4043.json
Dementia and Related Intracranial Pathologies
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4044.json
Aortic Dissection or Ruptured Aortic Aneurysm
active
2022-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4045.json
Oral Anticoagulant Medications
active
2023-02
us
hl7
rx
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4046.json
Cardiopulmonary Emergency
active
2025-02
us
hl7
icd
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4047.json
Cardiopulmonary Emergency
active
2025-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4048.json
Cardiopulmonary Emergency
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4049.json
Mechanical Circulatory Assist Device
active
2024-07
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4050.json
Mechanical Circulatory Assist Device
active
2025-02
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4052.json
Mechanical Circulatory Assist Device
active
2025-02
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4053.json
Pregnant State
active
2022-02
us
hl7
icd
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4054.json
Pregnant State
active
2024-07
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4055.json
Pregnant State
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3157.4056.json
Major Surgical Procedure
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3566.2.1005.json
Chronic Stable Angina
active
2024-02
us
hl7
icd
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3566.2.1006.json
Chronic Stable Angina
active
2023-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.3566.3.1002.json
Chronic Stable Angina
active
2021-04
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.1001.json
Hospice Encounter
active
2021-08
us
hl7
cms
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.1002.json
Hospice Encounter
active
2023-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.1003.json
Hospice Encounter
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.1004.json
Nutrition Services
active
2021-09
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.1005.json
Nutrition Services
active
2021-08
us
hl7
cms
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.1006.json
Nutrition Services
active
2022-03
us
hl7
vsac
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.1007.json
Hospice Care Ambulatory
active
2021-08
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.1008.json
Hospice Care Ambulatory
active
2021-08
us
hl7
cms
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1005.json
Office Visit
active
2023-11
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1020.json
Initial Hospital Inpatient Visit
active
2017-05
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1030.json
Discharge Services Hospital Inpatient Same Day Discharge
active
2017-05
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1035.json
Discharge Services Hospital Inpatient
active
2017-05
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1040.json
Outpatient Consultation
active
2024-02
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1050.json
Emergency Department Evaluation and Management Visit
active
2017-05
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1060.json
Nursing Facility Visit
active
2024-02
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1065.json
Discharge Services Nursing Facility
active
2017-05
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1080.json
Home Healthcare Services
active
2024-02
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1110.json
Preventive Care, Initial Office Visit, 0 to 17
active
2017-05
us
hl7
cpt
2
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1115.json
Preventive Care Services Initial Office Visit, 18 and Up
active
2017-05
us
hl7
cpt
6
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1120.json
Preventive Care, Established Office Visit, 0 to 17
active
2017-05
us
hl7
cpt
2
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1125.json
Preventive Care Services Established Office Visit, 18 and Up
active
2017-05
us
hl7
cpt
6
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1130.json
Preventive Care Services Individual Counseling
active
2017-05
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1135.json
Preventive Care Services Group Counseling
active
2017-05
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1215.json
Referral
active
2023-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1216.json
Face-to-Face Interaction
active
2017-05
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1221.json
Behavioral Health Follow up Visit
active
2020-03
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1222.json
Psychotherapy and Pharmacologic Management
active
2017-05
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1228.json
Detoxification Visit
active
2021-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1232.json
Audiology Visit
active
2017-05
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1233.json
Medical Disability Exam
active
2019-03
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1260.json
Telephone Visits
active
2025-02
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1261.json
Nursing Facility Visit
active
2018-03
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1262.json
Care Services in Long Term Residential Facility
active
2018-03
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1264.json
Office Visit
active
2025-01
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1265.json
Home Healthcare Services
active
2021-02
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1266.json
Outpatient Consultation
active
2020-03
us
hl7
sct
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1276.json
Frailty Encounter
active
2019-03
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1277.json
Outpatient Encounter
active
2025-03
us
hl7
cpt
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1278.json
Outpatient Encounter
active
2025-03
us
hl7
cms
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1279.json
Frailty Encounter
active
2019-03
us
hl7
cms
1
us.nlm.vsac
R4
ValueSet-2.16.840.1.113883.3.464.1003.101.11.1284.json
Outpatient Encounter
active
2023-11
us
hl7
sct
1